Gastroenterology is the 3rd largest therapy area which contributes 10% of the Indian Pharmaceutical Market (IPM) value. With the changes in lifestyle and VUCA (Volatile, Uncertain, Complex, Ambiguous) environment, the therapy area is set to grow significantly in the upcoming 10 years.
Alkem has always believed to evolve as per the need of the therapy and currently, Alkem holds 7% of the total revenue generated by this TA.
At present, Alkem is the 3rd largest company in the GI Therapy Area (TA) of IPM. Alkem has built its trust by developing several products for GI disorders like GERD, gastric ulcers, anti-emetic, constipation, hyperacidity, diarrhea, worm infestation, etc.
Some of the highlights of Alkem’s Gastroenterology portfolio are
* MAT March 2022